The CRISPR sector reported mixed, high‑impact developments: Intellia disclosed a fatality and reported it is awaiting a clinical‑hold letter from the FDA in its MAGNITUDE Phase III trial of nexiguran ziclumeran (nex‑z) after a patient experienced severe liver injury. Separately, CRISPR Therapeutics presented early clinical data showing a gene‑editing therapy produced large reductions in cholesterol and triglycerides in a Phase I study. Intellia’s program uses an in‑vivo LNP‑delivered CRISPR‑Cas9 approach for ATTR amyloidosis and the ongoing safety review and potential FDA action underscore regulatory scrutiny of in‑vivo genome editing. CRISPR Therapeutics’ lipid‑lowering readout renews enthusiasm about one‑time genetic treatments for cardiometabolic disease, but the juxtaposition of efficacy and safety events has prompted investors and regulators to reassess risk–benefit expectations across in‑vivo editing programs.